The Latest Cardiac and Vascular News
Gilde Healthcare and Norwest co-led round to commercialize the Hēlo® Thrombectomy Platform MENLO PARK, Calif., April 7, 2026 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”), a commercial-stage medical technology company focused on advancing the treatment of venous thromboembolism…
Pivotal trial evaluated the safety and efficacy of the Hēlo™ Thrombectomy System for the removal of blood clots from the lungs MENLO PARK, Calif., Nov. 3, 2025 /PRNewswire/ — Dr. Andrew Klein, ENGULF National Co-Principal Investigator at Piedmont Hospital in Atlanta, today presented the…
MENLO PARK, Calif., Sept. 2, 2025 /PRNewswire/ — E2 (Endovascular Engineering, Inc.) a medical device company advancing endovascular therapies for the treatment of venous thrombo-embolism (VTE), today announced the appointment of Justin Farry as its new Chief Financial Officer. A…
Pivotal trial evaluates safety and efficacy of the Hēlo™ PE Thrombectomy System for the removal of blood clots from the lungs MENLO PARK, Calif., June 23, 2025 /PRNewswire/ — E2 (Endovascular Engineering, Inc.), a medical device company advancing endovascular therapies, today announced…
MENLO PARK, Calif., Feb. 18, 2025 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”) has secured $42 million in an oversubscribed Series B financing to advance its next generation clot removal technology platform for venous thromboembolism (VTE). The round was co-led by 415 Capital and…
MENLO PARK, Calif., Aug. 20, 2024 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”), a pioneering medical device company at the forefront of advancing clot removal technologies for venous thromboembolism (VTE), has named Dan Rose as Chief Executive Officer (CEO). Former CEO and…
MENLO PARK, Calif., May 6, 2024 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”), a pioneering medical device company at the forefront of advancing clot removal technologies for venous thromboembolism (VTE), proudly announced positive safety and feasibility results from its ENGULF US…
MENLO PARK, Calif., Feb. 20, 2024 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”), a pioneering medical device company at the forefront of advancing clot removal technologies for venous thromboembolism (VTE), proudly announces the enrollment and treatment of the first patient in the…
MENLO PARK, Calif., Jan. 11, 2024 /PRNewswire/ — Endovascular Engineering (“E2”), a medical device company focused on the development and deployment of groundbreaking clot removal technologies that target venous thromboembolism (VTE), announced today FDA Investigational Device Exemption…
ENGULF Study utilizing next generation technology in targeting pulmonary embolism MENLO PARK, Calif., Oct. 31, 2023 /PRNewswire/ — Endovascular Engineering (“E2”), a mission driven, venture-backed, medical device company focused on the development and deployment of next generation clot…
